GlassScriptPhysician profile
Anuradha P Dua
NPI 1528079241
$4,715.03
in general payments reported to CMS, 2019-2025
35 companies · $1,959 in 2025
The $1,959 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $263 · 2021: $75.59 · 2022: $106 · 2023: $1,133 · 2024: $641 · 2025: $1,959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,732.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $545.14 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $518.77 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $471.92 | 2019-2025 | Korlym |
| Lilly USA, LLC | $410.81 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $385.77 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $242.27 | 2023-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $217.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.45 | 2019-2025 | Jardiance |
| Medtronic, INC. | $196.00 | 2023-2025 | Intellis Adaptivestim, Minimed 780g, Minimed 770g |
| Insulet Corporation | $179.82 | 2019-2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $155.91 | 2023-2025 | Strensiq |
| Dexcom, INC. | $131.06 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor |
| Amneal Pharmaceuticals LLC | $100.92 | 2023-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $98.80 | 2023-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $85.85 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $84.56 | 2025 | Tymlos |
| Recordati_rare_diseases_inc. | $84.06 | 2023-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $76.33 | 2025 | Rezdiffra |
| Beta Bionics, INC. | $68.90 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $66.09 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $52.65 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Janssen Pharmaceuticals, INC | $47.33 | 2020 | |
| Abbott Laboratories | $34.50 | 2022-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $33.53 | 2022-2023 | Verquvo, Steglatro |
| Antares Pharma, INC. | $32.81 | 2025 | Xyosted |
| Shire North American Group INC | $28.22 | 2019 | |
| Horizon Therapeutics Plc | $21.49 | 2019 | |
| Endo Pharmaceuticals INC. | $21.43 | 2020 | |
| Almatica Pharma LLC | $20.72 | 2025 | Teriparatide |
| Kyowa Kirin, INC. | $20.34 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.13 | 2024 | |
| Mannkind Corporation | $15.65 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.70 | 2023 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $13.08 | 2019 | |
| Amarin Pharma, INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuradha Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.